XML 40 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue related to Sanofi agreement:
Total	$ 54,851	$ 21,958	$ 17,548	$ 8,071	$ 26,837	$ 23,562	$ 21,416	$ 12,637	$ 102,428	$ 84,452	$ 36,567
Kite Pharma, Inc. ("Kite")
Revenue related to Sanofi agreement:
Total									34,350	25,517
Kite Pharma, Inc. ("Kite") | Recognition of upfront fee
Revenue related to Sanofi agreement:
Total									24,977	18,545
Kite Pharma, Inc. ("Kite") | Research services
Revenue related to Sanofi agreement:
Total									9,373	6,972
Sanofi
Revenue related to Sanofi agreement:
Total									22,680	13,516	12,258
Sanofi | Recognition of upfront fee
Revenue related to Sanofi agreement:
Total									3,494	4,013	1,769
Sanofi | Research services
Revenue related to Sanofi agreement:
Total									6,367	9,503	10,489
Sanofi | Milestone achievement
Revenue related to Sanofi agreement:
Total									12,819	0	0
Pfizer SB-525
Revenue related to Sanofi agreement:
Total									39,359	37,810	17,008
Pfizer SB-525 | Recognition of upfront fee
Revenue related to Sanofi agreement:
Total	$ 8,700								15,697	37,810	17,008
Pfizer SB-525 | Milestone achievement
Revenue related to Sanofi agreement:
Total									$ 23,662	$ 0	$ 0

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: